Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adagloxad simolenin + OBI-821
- Development stage
- Unknown
- Lead developer
- OBI Pharma
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Adagloxad simolenin (OBI‑822) combined with OBI‑821 is a therapeutic cancer vaccine designed as an active immunotherapy targeting the tumor-associated carbohydrate antigen (TACA) known as Globo H. Adagloxad simolenin consists of the Globo H antigen covalently linked to keyhole limpet hemocyanin (KLH), which acts as a carrier protein to enhance immune response. OBI‑821 is a saponin-based adjuvant, structurally similar to QS‑21, that boosts the immunogenicity of the vaccine. The combination aims to stimulate both humoral and cellular immune responses against tumors expressing Globo H, including triple-negative breast cancer and other solid tumors. The therapy is being developed primarily by OBI Pharma in collaboration with Memorial Sloan-Kettering Cancer Center[1][2][3][5][7].
- Brand names
- Adagloxad Simolenin
- Other names
- Cancer vaccine Globo-HGlobo H-KLHGlobo-H vaccine
02
Targets
Globo-H
Beyond the preview
Go deeper on adagloxad simolenin + OBI-821.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adagloxad simolenin + OBI-821.